Kerri E Rieger, MD
Undefined Physician Type (Specify) · Pleasanton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Rieger’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A101071 · Current
Licensed to practise in California · since 2007 · expires 2028-09-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$274,523
Medicare paid this office $274,523 for 2,871 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Pathology examination of tissue using a microscope, intermediate complexity | 2,453 | $130,467 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 431 | $27,515 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 513 | $21,303 | $31 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 242 | $18,858 | $71 |
| Microscopic genetic analysis of tumor, manual | 98 | $14,169 | $37 |
See all 22 services
| Pathology examination of tissue using a microscope, intermediate complexity | 2,453 | $130,467 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 431 | $27,515 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 513 | $21,303 | $31 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 242 | $18,858 | $71 |
| Microscopic genetic analysis of tumor, manual | 98 | $14,169 | $37 |
| Special stained specimen slides to identify organisms including interpretation and report | 335 | $13,380 | $23 |
| Antibody evaluation, each additional single antibody stain procedure | 81 | $8,766 | $25 |
| Short return visit (20+ min) | 43 | $4,679 | $79 |
| Return visit (30+ min) | 28 | $4,168 | $107 |
| Biopsy of related skin growth, first growth | 34 | $3,880 | $86 |
| Pathology examination of tissue using a microscope, moderately high complexity | 31 | $3,849 | $74 |
| Antibody evaluation, initial single antibody stain procedure | 81 | $2,723 | $31 |
| Destruction of precancer skin growth, 1 growth | 37 | $2,479 | $48 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 30 | $2,306 | $77 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $2,268 | $126 |
| Biopsy of related skin growth, each additional growth | 26 | $2,220 | $48 |
| Pathology examination of tissue using a microscope, moderately low complexity | 202 | $2,190 | $9 |
| Destruction of precancer skin growth, 2-14 growths | 34 | $1,953 | $7 |
| Genetic sequencing localization, initial procedure | 40 | $1,772 | $39 |
| New patient visit (30+ min) | 15 | $1,441 | $96 |
| Genetic sequencing localization, each additional procedure | 22 | $820 | $30 |
| Special stained specimen slides to examine tissue including interpretation and report | 21 | $258 | $10 |
Procedures Medicare counted
| Removal of skin lesions | 139 | More than 77% of doctors who do this |
| Skin biopsy | 63 | More than 71% of doctors who do this |
Who their Medicare patients are
2,871 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 16% · Women 47% · Also on Medicaid 11% · Health risk score 1.35. At or below the middle of the specialty; the typical undefined physician type clinician is at 1.67.
Conditions among them: High blood pressure 65% · Coronary heart disease 25% · Chronic kidney disease 23% · Cancer 22% · Diabetes 21% · Atrial fibrillation 19% · Heart failure 15% · Depression 14% · COPD 11% · Stroke 8% · Dementia 6%.
The office billed $3,437,264, Medicare allowed $362,164 and paid $274,523; for 8,616 services of 39 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 2,871 | 8,616 | 76 | 1.35 | $3,437,264 | $274,523 |
| 2023 | 2,473 | 7,102 | 76 | 1.37 | $2,638,349 | $233,308 |
| 2022 | 2,477 | 7,367 | 76 | 1.32 | $2,305,710 | $241,706 |
| 2021 | 2,107 | 6,106 | 75 | 1.37 | $1,343,288 | $210,026 |
| 2020 | 1,647 | 5,124 | 75 | 1.39 | $1,093,856 | $178,257 |
| 2019 | 1,990 | 6,041 | 76 | 1.42 | $1,139,986 | $200,920 |
| 2018 | 2,008 | 5,937 | 75 | 1.36 | $1,057,376 | $188,589 |
| 2017 | 1,525 | 4,022 | 75 | 1.35 | $721,356 | $136,076 |
| 2016 | 1,492 | 4,326 | 75 | 1.40 | $753,323 | $140,706 |
| 2015 | 1,291 | 3,879 | 75 | 1.31 | $665,249 | $126,261 |
| 2014 | 1,267 | 3,469 | 75 | 1.27 | $621,506 | $111,625 |
| 2013 | 1,045 | 2,619 | 75 | 1.26 | $452,477 | $92,691 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 2,095 | $117,614 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 336 | $20,363 | $26 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 229 | $18,907 | $77 |
| Special stained specimen slides to examine tissue, initial procedure | 416 | $17,672 | $31 |
| Special stained specimen slides to identify organisms including interpretation and report | 297 | $12,375 | $24 |
| Microscopic genetic analysis of tumor, manual | 59 | $8,285 | $39 |
| Antibody evaluation, each additional single antibody stain procedure | 76 | $8,172 | $26 |
| Short return visit (20+ min) | 39 | $4,957 | $83 |
| Pathology examination of tissue using a microscope, moderately high complexity | 28 | $2,927 | $77 |
| Antibody evaluation, initial single antibody stain procedure | 76 | $2,566 | $33 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 31 | $2,529 | $82 |
| Biopsy of related skin growth, first growth | 18 | $2,124 | $106 |
| Destruction of precancer skin growth, 1 growth | 24 | $1,959 | $49 |
| Return visit (30+ min) | 13 | $1,770 | $104 |
| Pathology examination of tissue using a microscope, moderately low complexity | 150 | $1,609 | $10 |
| Destruction of precancer skin growth, 2-14 growths | 23 | $1,560 | $6 |
| Genetic sequencing localization, initial procedure | 22 | $949 | $40 |
| Special stained specimen slides to examine tissue including interpretation and report | 17 | $322 | $11 |
2022: 20 services
| Pathology examination of tissue using a microscope, intermediate complexity | 2,152 | $117,451 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 361 | $26,077 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 428 | $18,156 | $32 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 197 | $16,509 | $76 |
| Special stained specimen slides to identify organisms including interpretation and report | 306 | $12,285 | $24 |
| Antibody evaluation, each additional single antibody stain procedure | 89 | $9,435 | $26 |
| Microscopic genetic analysis of tumor, manual | 66 | $8,734 | $39 |
| Pathology examination of tissue using a microscope, moderately high complexity | 43 | $5,173 | $77 |
| Short return visit (20+ min) | 40 | $4,435 | $78 |
| Biopsy of related skin growth, first growth | 27 | $3,160 | $90 |
| Antibody evaluation, initial single antibody stain procedure | 89 | $2,976 | $32 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 31 | $2,458 | $79 |
| Biopsy of related skin growth, each additional growth | 17 | $2,444 | $48 |
| Return visit (30+ min) | 13 | $1,656 | $103 |
| Pathology examination of tissue using a microscope, moderately low complexity | 142 | $1,591 | $10 |
| Destruction of precancer skin growth, 1 growth | 25 | $1,447 | $37 |
| Genetic sequencing localization, initial procedure | 32 | $1,387 | $41 |
| Destruction of precancer skin growth, 2-14 growths | 19 | $1,089 | $6 |
| Genetic sequencing localization, each additional procedure | 12 | $548 | $32 |
| Special stained specimen slides to examine tissue including interpretation and report | 18 | $347 | $11 |
2021: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,801 | $102,875 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 246 | $22,774 | $27 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 177 | $15,006 | $77 |
| Special stained specimen slides to examine tissue, initial procedure | 327 | $14,140 | $33 |
| Special stained specimen slides to identify organisms including interpretation and report | 264 | $11,005 | $25 |
| Antibody evaluation, each additional single antibody stain procedure | 68 | $8,372 | $28 |
| Microscopic genetic analysis of tumor, manual | 55 | $6,849 | $40 |
| Short return visit (20+ min) | 45 | $4,909 | $85 |
| Pathology examination of tissue using a microscope, moderately high complexity | 32 | $4,202 | $78 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 33 | $2,705 | $82 |
| Antibody evaluation, initial single antibody stain procedure | 68 | $2,642 | $34 |
| Biopsy of related skin growth, first growth | 21 | $2,116 | $92 |
| Return visit (30+ min) | 18 | $2,011 | $106 |
| Genetic sequencing localization, initial procedure | 29 | $1,577 | $41 |
| Destruction of precancer skin growth, 1 growth | 23 | $1,463 | $44 |
| Pathology examination of tissue using a microscope, moderately low complexity | 116 | $1,372 | $10 |
| Destruction of precancer skin growth, 2-14 growths | 20 | $903 | $6 |
| Special stained specimen slides to examine tissue including interpretation and report | 22 | $343 | $11 |
2020: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,363 | $84,223 | $35 |
| Special stained specimen slides to examine tissue, each additional procedure | 194 | $15,724 | $27 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 175 | $15,145 | $77 |
| Special stained specimen slides to examine tissue, initial procedure | 284 | $12,216 | $34 |
| Special stained specimen slides to identify organisms including interpretation and report | 220 | $10,602 | $25 |
| Antibody evaluation, each additional single antibody stain procedure | 80 | $9,430 | $28 |
| Microscopic genetic analysis of tumor, manual | 65 | $6,679 | $41 |
| Short return visit (20+ min) | 52 | $4,634 | $61 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 37 | $3,169 | $83 |
| Antibody evaluation, initial single antibody stain procedure | 79 | $2,970 | $35 |
| Pathology examination of tissue using a microscope, moderately high complexity | 20 | $2,619 | $82 |
| Destruction of precancer skin growth, 1 growth | 27 | $1,841 | $47 |
| Biopsy of related skin growth, first growth | 19 | $1,362 | $65 |
| Biopsy of related skin growth, each additional growth | 12 | $1,026 | $45 |
| Genetic sequencing localization, initial procedure | 21 | $986 | $43 |
| Destruction of precancer skin growth, 2-14 growths | 24 | $847 | $6 |
| Pathology examination of tissue using a microscope, moderately low complexity | 68 | $778 | $10 |
| Special stained specimen slides to examine tissue including interpretation and report | 25 | $492 | $12 |
2019: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,659 | $95,621 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 253 | $23,165 | $27 |
| Special stained specimen slides to examine tissue, initial procedure | 369 | $16,339 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 180 | $14,873 | $77 |
| Special stained specimen slides to identify organisms including interpretation and report | 262 | $11,695 | $24 |
| Antibody evaluation, each additional single antibody stain procedure | 84 | $8,893 | $27 |
| Pathology examination of tissue using a microscope, moderately high complexity | 37 | $5,649 | $80 |
| Microscopic genetic analysis of tumor, manual | 65 | $5,602 | $41 |
| Short return visit (20+ min) | 54 | $3,789 | $49 |
| Antibody evaluation, initial single antibody stain procedure | 84 | $3,170 | $34 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 32 | $2,496 | $78 |
| Destruction of precancer skin growth, 1 growth | 28 | $2,036 | $48 |
| Pathology examination of tissue using a microscope, moderately low complexity | 105 | $1,180 | $10 |
| Biopsy of related skin growth, first growth | 22 | $1,130 | $40 |
| Biopsy of related skin growth, each additional growth | 13 | $604 | $26 |
| Genetic sequencing localization, initial procedure | 14 | $587 | $39 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $452 | $3 |
| Special stained specimen slides to examine tissue including interpretation and report | 12 | $229 | $11 |
2018: 20 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,706 | $96,352 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 208 | $18,822 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 374 | $15,858 | $32 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 195 | $15,630 | $77 |
| Special stained specimen slides to identify organisms including interpretation and report | 252 | $12,668 | $24 |
| Antibody evaluation, each additional single antibody stain procedure | 64 | $6,705 | $26 |
| Pathology examination of tissue using a microscope, moderately high complexity | 21 | $3,802 | $78 |
| Microscopic genetic analysis of tumor, manual | 57 | $3,755 | $41 |
| Short return visit (20+ min) | 47 | $2,460 | $38 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 31 | $2,319 | $72 |
| Antibody evaluation, initial single antibody stain procedure | 65 | $2,255 | $33 |
| Destruction of precancer skin growth, 1 growth | 28 | $1,428 | $40 |
| Pathology examination of tissue using a microscope, moderately low complexity | 103 | $1,050 | $10 |
| Genetic sequencing localization, initial procedure | 20 | $978 | $41 |
| Biopsy of single growth of skin and/or tissue | 30 | $837 | $24 |
| Biopsy of each additional growth of skin and/or tissue | 19 | $588 | $17 |
| Genetic sequencing localization, each additional procedure | 12 | $545 | $32 |
| Destruction of precancer skin growth, 2-14 growths | 26 | $326 | $2 |
| Examination of archival tissue for genetic analysis | 14 | $273 | $18 |
| Special stained specimen slides to examine tissue including interpretation and report | 16 | $245 | $11 |
2017: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,248 | $70,641 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 167 | $13,296 | $76 |
| Special stained specimen slides to examine tissue, each additional procedure | 138 | $11,806 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 235 | $10,880 | $32 |
| Special stained specimen slides to identify organisms including interpretation and report | 178 | $7,527 | $25 |
| Pathology examination of tissue using a microscope, moderately high complexity | 29 | $5,135 | $78 |
| Antibody evaluation, each additional single antibody stain procedure | 37 | $3,907 | $26 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 31 | $2,533 | $79 |
| Short return visit (20+ min) | 39 | $1,676 | $34 |
| Microscopic genetic analysis of tumor, manual | 20 | $1,617 | $51 |
| Antibody evaluation, initial single antibody stain procedure | 37 | $1,440 | $33 |
| New patient visit (30+ min) | 14 | $918 | $66 |
| Destruction of precancer skin growth, 1 growth | 23 | $912 | $36 |
| Pathology examination of tissue using a microscope, moderately low complexity | 69 | $726 | $10 |
| Biopsy of single growth of skin and/or tissue | 18 | $496 | $26 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $307 | $19 |
| Special stained specimen slides to examine tissue including interpretation and report | 13 | $207 | $11 |
| Destruction of precancer skin growth, 2-14 growths | 19 | $143 | $2 |
2016: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,199 | $65,976 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 158 | $15,489 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 165 | $13,141 | $77 |
| Special stained specimen slides to examine tissue, initial procedure | 270 | $11,203 | $32 |
| Special stained specimen slides to identify organisms including interpretation and report | 211 | $9,439 | $25 |
| Antibody evaluation, each additional single antibody stain procedure | 53 | $4,750 | $25 |
| Pathology examination of tissue using a microscope, moderately high complexity | 21 | $3,825 | $78 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 46 | $3,529 | $77 |
| Short return visit (20+ min) | 49 | $2,766 | $40 |
| Microscopic genetic analysis of tumor, manual | 35 | $2,243 | $50 |
| Antibody evaluation, initial single antibody stain procedure | 53 | $2,100 | $33 |
| Destruction of precancer skin growth, 1 growth | 18 | $1,123 | $43 |
| New patient visit (30+ min) | 16 | $998 | $62 |
| Biopsy of single growth of skin and/or tissue | 23 | $955 | $33 |
| Pathology examination of tissue using a microscope, moderately low complexity | 67 | $746 | $10 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $490 | $22 |
| Special stained specimen slides to examine tissue including interpretation and report | 23 | $451 | $11 |
| Destruction of precancer skin growth, 2-14 growths | 16 | $203 | $2 |
2015: 16 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,031 | $58,326 | $33 |
| Antibody evaluation, initial single antibody stain procedure | 59 | $11,761 | $38 |
| Special stained specimen slides to identify organisms including interpretation and report | 215 | $10,826 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 138 | $10,709 | $75 |
| Special stained specimen slides to examine tissue, initial procedure | 234 | $9,504 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 119 | $8,785 | $19 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 56 | $4,349 | $75 |
| Pathology examination of tissue using a microscope, moderately high complexity | 22 | $2,885 | $74 |
| Short return visit (20+ min) | 34 | $1,853 | $41 |
| Microscopic genetic analysis of tumor, manual | 28 | $1,596 | $50 |
| New patient visit (30+ min) | 21 | $1,207 | $57 |
| Destruction of precancer skin growth, 1 growth | 21 | $1,023 | $43 |
| Pathology examination of tissue using a microscope, moderately low complexity | 64 | $747 | $10 |
| Biopsy of single growth of skin and/or tissue | 18 | $526 | $26 |
| Special stained specimen slides to examine tissue including interpretation and report | 21 | $487 | $11 |
| Destruction of precancer skin growth, 2-14 growths | 17 | $183 | $2 |
2014: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,024 | $56,579 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 166 | $12,950 | $71 |
| Special stained specimen slides to identify organisms including interpretation and report | 203 | $8,839 | $24 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 210 | $7,658 | $27 |
| Antibody evaluation, initial single antibody stain procedure | 37 | $7,359 | $39 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 83 | $6,730 | $77 |
| Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 122 | $5,219 | $11 |
| Pathology examination of tissue using a microscope, moderately high complexity | 19 | $2,585 | $76 |
| Microscopic genetic analysis of tumor, manual | 27 | $1,566 | $49 |
| Genetic sequencing localization, initial procedure | 11 | $969 | $54 |
| Pathology examination of tissue using a microscope, moderately low complexity | 49 | $548 | $10 |
| Special stained specimen slides to examine tissue including interpretation and report | 17 | $249 | $11 |
2013: 13 services
| Pathology examination of tissue using a microscope, intermediate complexity | 827 | $41,215 | $32 |
| Special stained specimen slides to examine tissue, initial procedure | 128 | $17,295 | $38 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 128 | $10,864 | $73 |
| Special stained specimen slides to identify organisms including interpretation and report | 162 | $7,514 | $23 |
| Antibody evaluation, initial single antibody stain procedure | 23 | $4,337 | $38 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 44 | $3,379 | $72 |
| Short return visit (20+ min) | 38 | $1,810 | $36 |
| Pathology examination of tissue using a microscope, moderately high complexity | 12 | $1,185 | $74 |
| New patient visit (30+ min) | 17 | $970 | $57 |
| Microscopic genetic analysis of tumor, manual | 16 | $888 | $47 |
| Biopsy of single growth of skin and/or tissue | 19 | $702 | $33 |
| Pathology examination of tissue using a microscope, moderately low complexity | 40 | $432 | $10 |
| Special stained specimen slides to examine tissue including interpretation and report | 20 | $276 | $11 |
Medicaid work
$46,965 in 2024
Medicaid paid $46,965 for 1,250 billed services this clinician did in 2024, up to 95 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 718 | $27,631 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 221 | $9,210 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 101 | $3,840 |
| TISSUE EXAM BY PATHOLOGIST | 108 | $3,274 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 102 | $3,009 |
| 2024 | 1,250 | 5 | 95 | $46,965 |
| 2023 | 1,193 | 5 | 113 | $53,794 |
| 2022 | 870 | 5 | 73 | $36,569 |
| 2021 | 677 | 4 | 71 | $27,064 |
| 2020 | 479 | 3 | 58 | $20,312 |
| 2019 | 549 | 3 | 57 | $24,317 |
| 2018 | 632 | 3 | 52 | $27,364 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 774 | $34,980 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 204 | $9,764 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 105 | $5,488 |
| TISSUE EXAM BY PATHOLOGIST | 82 | $2,514 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 28 | $1,049 |
2022
| TISSUE EXAM BY PATHOLOGIST | 597 | $23,729 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 164 | $6,226 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 57 | $4,254 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 24 | $1,628 |
| TISSUE EXAM BY PATHOLOGIST | 28 | $733 |
2021
| TISSUE EXAM BY PATHOLOGIST | 487 | $18,923 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 149 | $5,436 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 28 | $1,765 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 13 | $940 |
2020
| TISSUE EXAM BY PATHOLOGIST | 376 | $15,885 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 84 | $3,663 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 19 | $763 |
2019
| TISSUE EXAM BY PATHOLOGIST | 440 | $19,664 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 52 | $2,527 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 57 | $2,126 |
2018
| TISSUE EXAM BY PATHOLOGIST | 499 | $22,018 |
| Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) | 119 | $4,918 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 14 | $428 |
Drugs they prescribed that Part D paid
$147,992
Pharmacies billed $147,992 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
105 generic and fewer than 11 brand-name prescriptions · $147,992 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ketoconazole | 25 | $433 | $17 |
| Hydrocortisone | 14 | $148 | $11 |
Year by year
| 2024 | 115 | 24 | None | None | $147,992 |
| 2023 | 106 | 30 | 0% (0) | None | $116,008 |
| 2022 | 72 | 23 | 0% (0) | None | $159,046 |
| 2021 | 102 | 27 | 0% (0) | 12% | $162,259 |
| 2020 | 102 | 24 | 0% (0) | None | $58,110 |
| 2019 | 60 | 22 | 0% (0) | None | $118,462 |
| 2018 | 62 | 29 | 0% (0) | None | $81,769 |
| 2017 | 79 | 26 | 0% (0) | None | $5,161 |
| 2016 | 96 | 36 | 0% (0) | 26% | $8,250 |
| 2015 | 55 | 18 | 0% (0) | 44% | $6,199 |
| 2013 | 90 | 31 | 0% (0) | 26% | $5,193 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Fluocinonide | 14 | $836 | $60 |
| Ketoconazole | 19 | $232 | $12 |
| Triamcinolone Acetonide | 15 | $115 | $8 |
| Hydrocortisone | 11 | $114 | $10 |
2022: 1 drug
| Hydrocortisone | 11 | $264 | $24 |
2021: 3 drugs
| Clobetasol Propionate | 11 | $540 | $49 |
| Hydrocortisone | 17 | $247 | $15 |
| Triamcinolone Acetonide | 14 | $133 | $9 |
2020: 3 drugs
| Fluocinonide | 14 | $792 | $57 |
| Ketoconazole | 12 | $182 | $15 |
| Triamcinolone Acetonide | 18 | $178 | $10 |
2017: 1 drug
| Desonide | 11 | $996 | $91 |
2016: 1 drug
| Fluocinonide | 19 | $1,942 | $102 |
2015: 2 drugs
| Desonide | 11 | $2,688 | $244 |
| Methotrexate | 17 | $828 | $49 |
2013: 2 drugs
| Fluocinonide | 25 | $1,952 | $78 |
| Ketoconazole | 19 | $374 | $20 |
Money from drug and device companies
$11,750 in 2023
| 2023 | 1 | 2 | $11,750 | $11,750 |
| 2022 | 1 | 1 | $4,978 | $4,978 |
| 2020 | 2 | 3 | $30,600 | $30,600 |
| 2019 | 1 | 8 | $7,500 | $8,704 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | None | $11,750 | 2 payments
|
See all 2 published payments
| Pfizer | Consulting · 2023-04-03 | None | $11,000 |
| Pfizer | Consulting · 2023-04-03 | None | $750 |
See earlier years (2022, 2020, 2019)
2022: $4,978
| Kyowa Kirin | Poteligeo | $4,978 | 1 payment
|
2020: $30,600
| Kyowa Kirin | Sancuso | $18,600 | 2 payments
|
| Pfizer | None | $12,000 | 1 payment
|
2019: $8,704
| Kyowa Kirin | Poteligeo | $8,704 | 8 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · Pf07038124 Brepocitinib Dazukibart Pf06763809 Dekavil Pf06817024 Pf06480605 Ritlecitinib Zimlovisertib Pf06826647 Pf06835375 Multi Product Pf07054894 Pf06473871 Clinical Publication Program · 2024 | This clinician | $3,200 |
| PFIZER INC. · Brepocitinib Clinical Publication Program · 2023 | This clinician | $330 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1336333475
- Licence
- CA A101071California A101071: Current · expires 2028-09-30
- Trained
- Stanford University School of Medicine, 2006
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-08-31
- NPI last updated
- 2026-07-09
- NPI record certified
- 2026-07-09
This is when the NPI record was last certified, not a medical board exam.